The present invention provides therapeutic compounds of the following formula I: or pharmaceutically acceptable salts, hydrates, or solvates thereof that are therapeutic or anticancer agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

##STR00001##

The present invention provides therapeutic compounds of the following formula I: or pharmaceutically acceptable salts, hydrates, or solvates thereof that are therapeutic or anticancer agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

##STR00001##

Compositions and methods for the treatment of bacterial infections include conjugates containing an Fc domain covalently linked to one or more monomers of cyclic heptapeptides or one or more dimers of cyclic heptapeptides. In particular, conjugates can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

The present invention provides antimicrobial polymyxin compounds of the following formula I: ##STR00001##
or pharmaceutically acceptable salts, hydrates, or solvates thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

The present invention provides antimicrobial polymyxin compounds of the following formula I: ##STR00001##
or pharmaceutically acceptable salts, hydrates, or solvates thereof that are antibacterial agents, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

The present invention relates to a polymyxin derivative of formula (I) ##STR00001## wherein R1 is Dab R2 is Thr R3 is DThr R4 is Dab R5 is Dab R6 is DPhe R7 is Leu R8 is Abu R9 is Dab; R10 is Thr; and R(FA) is octanoyl;
and pharmaceutically acceptable salts thereof. The invention further relates to their use in the treatment of infections caused by Gram-negative bacteria.

The present invention relates to a polymyxin derivative of formula (I) ##STR00001## wherein R1 is Dab R2 is Thr R3 is DThr R4 is Dab R5 is Dab R6 is DPhe R7 is Leu R8 is Abu R9 is Dab; R10 is Thr; and R(FA) is octanoyl;
and pharmaceutically acceptable salts thereof. The invention further relates to their use in the treatment of infections caused by Gram-negative bacteria.

Field of application: The invention relates to medicine and pharmacy and allows to obtain new pharmaceutical compositions based on polymyxin for the treatment of severe infectious diseases, but not possessing nephrotoxic properties in therapeutic doses. Technical result: New combined dosage forms based on the antibiotic polymyxin with low nephrotoxicity and high activity.

Field of application: The invention relates to medicine and pharmacy and allows to obtain new pharmaceutical compositions based on polymyxin for the treatment of severe infectious diseases, but not possessing nephrotoxic properties in therapeutic doses. Technical result: New combined dosage forms based on the antibiotic polymyxin with low nephrotoxicity and high activity.

The invention relates to novel compounds with the ability to link an immune response to a pathogen, to the use of said compounds in a disease or disorder mediated and/or caused by an infective agent, to compositions containing said compounds, processes for their preparation and to novel intermediates used in said process.